×
New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more
https://www.ashclinicalnews.org/news/ash-directions/new-ash-congressional-fellow-accepting-submissions-2019-ash-annual-meeting/

Jul 1st, 2019 - Zachary Kiser, PhD Next ASH Congressional Fellow Is Bound for Capitol Hill Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow. Dr. Kiser, a post-doctoral fellow in the National Institutes of Health–funded Research Program at the University of Minnesota, will spend the 2019-2020 academic year in Washington, D.C., where he wil...

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma
https://ascopost.com/News/60199

Jun 26th, 2019 - Today, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The application received approval through the FDA’s Real-Time Oncology Review pilot program. The approval is based on results from t...

The use of direct oral anticoagulants for extended duration thromboprophylaxis in medic...
https://doi.org/10.1007/s11239-019-01900-2
Journal of Thrombosis and Thrombolysis; Alshouimi RA, Al Rammah SM et. al.

Jun 21st, 2019 - The extended use of thromboprophylaxis with direct oral anticoagulants (DOACs) for more than 30 days has been evaluated as an alternative for the standard duration thromboprophylaxis (7-10 days) with low molecular weight heparin in medically ill patients to reduce the risk of venous thromboembolism (VTE) after hospital discharge. EMBASE and MEDLINE were searched for studies evaluating extended ...

Selected Abstracts From the 2019 ASCO Annual Meeting
https://ascopost.com/issues/june-10-2019/selected-abstracts-from-the-2019-asco-annual-meeting/

Jun 9th, 2019 - Plasma Cell Dyscrasias Syed Ali Abutalib, MD Ola Landgren, MD, PhD To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for plasma cell dyscrasias, particularly multiple myeloma. For full details of these study abstracts, visit http://abstracts.asco.org. ABSTR...

Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More
https://www.ashclinicalnews.org/news/the-society-pages/remembering-milton-h-freedman-caryn-lerman-named-director-usc-norris/

Jun 1st, 2019 - Remembering Milton H. Freedman (1919 – 2019) Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21, 2019. Dr. Freedman was born in Atlanta, where he spent almost his entire life, except for a stint in the U.S. Navy as a flight surgeon during World War II and a hematology fellowship at Pratt Diagnostic Hospital (now Tufts Medical Center) in Bost...

Evolving paradigm in thrombophilia screening.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687403
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis; Ashraf N, Visweshwar N et. al.

May 30th, 2019 - : The role of genetic thrombophilia screening for identifying a hypercoagulable state in the management of venous thromboembolism. We searched MEDLINE and EMBASE from 1995 to 2017, the websites of the professional bodies including American Society of Hematology, British Society of Hematology, International Society of Thrombosis and Hemostasis, College of American Pathologists, American College ...

Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-...
https://doi.org/10.1097/PPO.0000000000000379
Cancer Journal (Sudbury, Mass.); Shah UA, Smith EL

May 28th, 2019 - Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially ove...

Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible...
https://doi.org/10.1016/j.clml.2019.04.009
Clinical Lymphoma, Myeloma & Leukemia; Cao Y, Wan N et. al.

May 27th, 2019 - Many new regimens have been applied to newly diagnosed transplant-ineligible multiple myeloma, but no head-to-head research has been performed to compare the efficacy of these treatments. Currently lenalidomide plus dexamethasone (Rd) is one of the standard treatments. Our aim was to make a comparison of these treatments to Rd by a network meta-analysis. We performed a systematic review and net...

Debating the Role of Opioids in the Management of Chronic Cancer Pain
https://ascopost.com/issues/may-25-2019/debating-the-role-of-opioids-in-the-management-of-chronic-cancer-pain/

May 24th, 2019 - A Conversation With Leslie J. Blackhall, MD, and Charles F. von Gunten, MD, PhD Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving opioids, including both p...

Charles G. Mullighan, MBBS (Hons), MSc, MD, Named St. Jude Comprehensive Cancer Center Deputy Director
https://ascopost.com/issues/may-25-2019/charles-mullighan-named-st-jude-comprehensive-cancer-center-deputy-director/

May 24th, 2019 - The St. Jude Children’s Research Hospital Comprehensive Cancer Center has appointed Charles G. Mullighan, MBBS (Hons), MSc, MD, as its new Deputy Director. In this new position, Dr. Mullighan will help guide precision medicine and preclinical strategic research initiatives for the Center, which is the nation’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted s...

Erythropoiesis-Stimulating Agents Recommended for Some Patients With Cancer and Anemia
https://ascopost.com/issues/may-25-2019/erythropoiesis-stimulating-agents-recommended-for-some-patients-with-cancer-and-anemia/

May 24th, 2019 - ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for use of erythropoiesis-stimulating agents to manage anemia in patients with cancer.1 “The current update aims to increase awareness of recent developments regarding the use of erythropoiesis-stimulating agents in patients with cancer. New information has emerged that may not be widely disseminate...

Anjali Mishra, PhD, and Nitin Chakravarti, PhD, Join Sidney Kimmel Cancer Center at Jefferson Health
https://ascopost.com/issues/may-25-2019/staff-join-sidney-kimmel-cancer-center-at-jefferson-health/

May 24th, 2019 - The Sidney Kimmel Cancer Center–Jefferson Health (SKCC) recently welcomed Anjali Mishra, PhD, and Nitin Chakravarti, PhD, to its team of researchers focused on hematologic cancers. Both Drs. Mishra and Chakravarti are Assistant Professors in the Department of Medical Oncology. Dr. Mishra is a cancer biologist studying the pathogenetic mechanisms in cytokine-driven leukemias and lymphomas. Her r...

ASH President Comments on Medicare Proposal for CAR T-Cell Therapy
https://ascopost.com/issues/may-25-2019/ash-president-comments-on-medicare-proposal-for-car-t-cell-therapy/

May 24th, 2019 - Roy Silverstein, MD Recently, the Centers for Medicare & Medicaid Services (CMS) proposed to improve the reimbursement currently given to hospitals that provide chimeric antigen receptor (CAR) T-cell therapy to patients with blood cancer as part of the Fiscal Year 2020 Inpatient Prospective Payment System proposed rule. American Society of Hematology (ASH) President Roy Silverstein, MD, of the ...

Expert Point of View: Irene Ghobrial, MD, and Monica M. Bertagnolli, MD, FACS, FASCO
https://ascopost.com/issues/may-25-2019/epov-irene-ghobrial-and-monica-bertagnolli/

May 24th, 2019 - Irene Ghobrial, MD Irene Ghobrial, MD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston, who has conducted seminal trials in smoldering myeloma, commented on the phase III E3A06 study. Asked by The ASCO Post whether E3A06 settles the issue of treating smoldering disease, Dr. Ghobrial responded, “Yes, and no.” “Yes, because this is the first well-randomized phase III trial in t...

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeti...
https://doi.org/10.1016/j.clml.2019.03.008
Clinical Lymphoma, Myeloma & Leukemia; Terpos E, Ntanasis-Stathopoulos I et. al.

May 11th, 2019 - Herein, we summarize the novel clinical data for multiple myeloma (MM) that were presented in the 2019 Annual Meeting of the American Society of Hematology. Triplet regimens including lenalidomide-dexamethasone for high-risk smoldering MM are effective but longer follow-up data are needed. Among transplant-eligible, newly diagnosed MM (NDMM) patients, carfilzomib- and daratumumab-based combinat...

CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain
https://ascopost.com/issues/may-10-2019/cdc-issues-clarification-on-guideline-for-prescribing-opioids-for-chronic-pain/

May 9th, 2019 - ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) recently acknowledged receipt of a key clarification1 from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification regarding the CDC’s Guideline for Prescribing Opioids for Chronic Pain2 came as a result of a collabo...

Hematologist Francesco Lo Coco, MD, Dies in Rome at 63
https://ascopost.com/issues/may-10-2019/francesco-lo-coco-dies-in-rome-at-63/

May 9th, 2019 - Francesco Lo Coco, MD Hematologist Francesco Lo Coco, MD, known for his research accomplishments in both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL), died in Rome on March 3, 2019. He was 63. After graduating from the Medical School in Pisa, he moved to La Sapienza University of Rome in 1981. From 1992 to 1994, Dr. Lo Coco was a visiting researcher at the Institute for C...

CMS proposes payment increase for administering CAR T in the hospital
https://www.mdedge.com/hematology-oncology/article/200156/practice-management/cms-proposes-payment-increase-administering?channel=39313
Alicia Gallegos

May 3rd, 2019 - Hospitals could get a payment bump for administering chimeric antigen receptor (CAR) T-cell therapies under a proposed rule issued by the Centers for Medicare & Medicaid Services. Penn Medicine CAR T cells ready for infusion The proposal calls for raising the new technology add-on payment (NTAP) associated with the therapies from 50% of the technology to 65%, an increase from $186,500 to $242,4.

Training curriculum to help patient representatives participate meaningfully in the dev...
https://doi.org/10.1136/bmjebm-2019-111186
BMJ Evidence-based Medicine; Daraz L, Webb S et. al.

May 1st, 2019 - Patient participation in the development of clinical practice guidelines (CPGs) is critical for validity and trust. Many guideline panels now include patient representatives. Engagement of these individuals may be improved by training them about the process and their role before they join a guideline panel. To aid patient representatives in engagement in the improvement of guidelines, we develo...

Biomedical Research Community Concerned About Cuts in Proposed 2020 Budget
https://www.ashclinicalnews.org/news/proposed-2020-budget-slash-cancer-funding/

May 1st, 2019 - On March 11, President Donald Trump released his proposed fiscal year 2020 budget, called “A Budget for a Better America,” that includes a substantial 12-percent cut to funding for the U.S. Department of Health and Human Services (HHS). This amounts to a $4.7-billion decrease in funding for the National Institutes of Health (NIH) – the U.S.’s largest provider of funding for biomedical research....